Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
33.6% Return Seen to Date on SmarTrend Stemline Therape Call (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 2 months, Stemline Therape has returned 33.59% as of today's recent price of $8.77....

STML : 9.03 (+0.11%)
Stemline Therapeutics Announces ELZONRIS(R) Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp)...

STML : 9.03 (+0.11%)
Stemline Therape Has Returned 29.3% Since SmarTrend Recommendation (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 2 months, Stemline Therape has returned 29.34% as of today's recent price of $9.33....

STML : 9.03 (+0.11%)
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data...

STML : 9.03 (+0.11%)
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data...

STML : 9.03 (+0.11%)
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 9.03 (+0.11%)
17.4% Return Seen to Date on SmarTrend Stemline Therape Call (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 1 month, Stemline Therape has returned 17.38% as of today's recent price of $10.91....

STML : 9.03 (+0.11%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , ADMS , MRTX, CHRS , RTRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ADMS : 3.98 (-0.50%)
STML : 9.03 (+0.11%)
MRTX : 76.37 (-12.29%)
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 9.03 (+0.11%)
Downtrend Call Working As Stemline Therape Stock Falls 16.7% (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 4 weeks, Stemline Therape has returned 16.70% as of today's recent price of $11.00....

STML : 9.03 (+0.11%)
Stemline Therape Has Returned 14.3% Since SmarTrend Recommendation (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 3 weeks, Stemline Therape has returned 14.27% as of today's recent price of $11.32....

STML : 9.03 (+0.11%)
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 9.03 (+0.11%)
After Yesterday's Decline of 5.32%, Stemline Therape Offers Investors Better Value

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $12.69 to a high of $13.72. Yesterday, the shares fell 5.3%, which took the trading range below the 3-day low of...

STML : 9.03 (+0.11%)
Global Baculoviral IAP Repeat Containing Protein 5 Market Insights, Forecast to 2019 Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

The market size of Baculoviral IAP Repeat Containing Protein 5 is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million...

IMV.TO : 3.90 (+10.48%)
STML : 9.03 (+0.11%)
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 9.03 (+0.11%)
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 120.56 (+0.17%)
STML : 9.03 (+0.11%)
Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 120.56 (+0.17%)
STML : 9.03 (+0.11%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , AMAG , RDUS , FLXN , RARE )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

AMAG : 11.20 (-1.88%)
RDUS : 27.31 (-1.09%)
STML : 9.03 (+0.11%)
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS(R)

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers...

STML : 9.03 (+0.11%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , CHRS , CLVS , MNTA , EBS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CHRS : 19.27 (+0.42%)
CLVS : 3.34 (-8.74%)
STML : 9.03 (+0.11%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar